

Paradigm Increases Presence at OARSI World Congress 2023

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to provide shareholders additional information on Paradigm’s involvement at the Osteoarthritis Research Society International (**OARSI**) 2023 World Congress, following the update in relation to this conference already announced on 31 January as part of the Company's December 2022 Quarterly Activities Report. As previously announced, this international conference will be held in Denver, Colorado from 17–20 March 2023. It is considered a prestigious conference and Paradigm will participate in three events, as follows:

1. As previously announced, Paradigm has been invited to speak, at the Clinical Trials Symposium (**CTS** Congress) scheduled for Thursday 16 March 2023, the evening before the official start of the OARSI annual international congress.

Paradigm's invitation to the Symposium represents recognition of Paradigm's OA clinical development programs. This event provides an opportunity for a limited number of presentations from companies in development of therapies for the treatment of osteoarthritis.

The proposed agenda for the CTS is:

- (i) Clinical Trial Update: Lessons learned from the first 5 years of CTS (2017–2023, from Las Vegas to Denver). Presenting will be Virginia Byers Kraus MD, PhD, a professor in the Departments of Medicine, Pathology, and Orthopaedic Surgery, and a member of the Duke Molecular Physiology Institute (DMPI). Dr Kraus is a practicing rheumatologist with expertise in musculoskeletal research related to osteoarthritis. Dr. Kraus’ career has focused on translational research into the discovery and validation of biomarkers for early osteoarthritis detection, prediction of progression, and monitoring of disease status.
 - (ii) Clinical updates from selected companies in clinical development. Dr. Donna Skerrett, Paradigm's Chief Medical Officer, will present the technology, mechanism of action, and clinical translation of Paradigm's ongoing OA program.
2. Paradigm has previously reported that an abstract detailing the day 56 results from the phase 2 synovial fluid biomarker clinical trial (PARA_OA_008) has been accepted for a poster presentation at the 2023 OARSI World Congress on Osteoarthritis. Paradigm’s Dr. Mukesh Ahuja, Global Clinical Head of OA will be conducting the poster presentation.
3. Paradigm will additionally be conducting a sponsored oral theatre presentation to OARSI conference attendees. Paradigm’s Chief Scientific Officer Dr. Ravi Krishnan and Dr. Mukesh Ahuja will be conducting the oral presentation which will cover Paradigm’s global OA program, including the day 56 top-line data from the PARA_OA_008 clinical trial and proposed mechanism of action.

Paradigm's Managing Director Paul Rennie said, *"It is very exciting for our Company to be invited to provide an oral presentation to the OARSI Clinical Trial Symposium. This presentation will provide an update on our phase 3 OA clinical trial (PARA_OA_002) along with the top-line results of our disease modifying phase 2 OA clinical trial (PARA_OA_008). Attendees to the CTS will hear a summary of the results from OA clinical trials over the past 5 years. Attendees at this conference are scientists and representatives from pharma companies with an interest in OA clinical trials. Paradigm expects to report on the 6-month follow-up data from PARA_OA_008 shortly after the OARSI CTS,"*.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com